This CEO Wants To Beat Blindness -Guest: Dr. Shankar Musunuri - Ocugen, Chairman, Chief Executive Officer, and Co-Founder Shares Timeless Advice - $OCGN

Guest: Dr. Shankar Musunuri - Ocugen, Chairman, Chief Executive
Officer, and Co-founder





Website:


www.ocugen.com





Ticker: OCGN





Bio:


Dr. Shankar Musunuri is Chairman, CEO and Co-Founder of Ocugen.
The company (NASDAQ: OCGN) is a publicly traded biotechnology
company focused on discovery, development, commercialization of
gene therapies, cell therapies, biologicals, and vaccines, based
in Malvern, Pennsylvania. Dr. Musunuri transformed Ocugen from a
start-up into a cutting-edge science-based biotech powerhouse
with three distinct first-in-class platform technologies focused
on ophthalmology with a first-in-class modifier gene therapy
platform targeting rare as well as large blindness diseases,
orthopedics with a regenerative cell therapy platform, and
infectious diseases with an inhalation vaccine platform targeting
Covid-19, flu, and a combination vaccine for both COVID-19 and
flu. Ocugen anticipates launching products from these
game-changing platform technologies within the next few years.
The company’s mission is to develop cutting-edge innovations for
people with serious diseases and conditions with a commitment to
ensuring global market access.





Dr. Musunuri is a seasoned biotech veteran with 30+ years’
experience advancing and commercializing a diverse portfolio of
products. Prior to co-founding Ocugen in 2013, he held leadership
roles at numerous companies ranging from large multinational
biotechnology companies such as Wyeth and Pfizer, to novel
start-up biotech companies. During his 15 years at Pfizer, he
gained extensive product launch and life-cycle management
experience including leading the Global Operations Team for
Prevnar 13, the world’s best-selling vaccine. Dr. Musunuri then
founded Nuron Biotech, Inc., which grew into a commercial company
in less than three years.





Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the
University of Connecticut—where he also received a Distinguished
Alumnus Award. He also received an MBA from Duke University,
where today he serves on the University’s Innovation &
Entrepreneurship Board of Advisors. Dr. Musunuri serves as both
CEO and Chairman of the board of Ocugen. He has received numerous
leadership awards including Most Admired CEO Award by
Philadelphia Business Journal, the 2023 Healthcare Power 100
(ranked 22nd) in PA and the 2023 AAPI Power 100 (ranked 11th) in
PA. He is also a Board Member of the Musunuri Family Foundation,
a non-profit that provides college scholarships for high school
students. Dr. Musunuri has a passion for addressing diseases and
conditions which lack effective treatments. This commitment is
reflected in Ocugen’s mission of relentlessly pursuing courageous
innovation on behalf of patients with unmet medical needs.





About Ocugen, Inc.


Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies,
biologics, and vaccines that improve health and offer hope for
patients across the globe. We are making an impact on patients’
lives through courageous innovation—forging new scientific paths
that harness our unique intellectual and human capital. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with a single product, and we are
advancing research in infectious diseases to support public
health and orthopedic diseases to address unmet medical needs.





Discover more at www.ocugen.com